RAC Regulatory Affairs Certification RAC-US Dumps Full Questions with Free PDF Questions to Pass
100% Updated RAPS RAC-US Enterprise PDF Dumps
NEW QUESTION 35
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 500 patients for three months
- B. 200 patients for nine months
- C. 3.000 total patient exposures
- D. 100 patients for 12 months
Answer: D
NEW QUESTION 36
A drug product presents degradation during the manufacturing process. In addition to the amount, what information should be provided FIRST in order to use API overage?
- A. Property
- B. Justification
- C. Formulation
- D. Specification
Answer: B
NEW QUESTION 37
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject's hospitalization is prolonged during the clinical trial.
- B. Subject is hospitalized for the purpose of product administration.
- C. Subject's hospitalization is due to an unscheduled hip operation.
- D. Subject is hospitalized due to complications of the product administration.
Answer: B
NEW QUESTION 38
During a regulatory authority inspection of a manufacturing site, the inspector observes that one of the medicinal products manufactured at the site is not GMP compliant. The product
Is distributed globally.
Which of the following is the most appropriate action to take FIRST?
- A. Assess the potential safety risk.
- B. Withdraw the affected product from the markets.
- C. Notify the global regulatory authorities.
- D. Send a "Dear Dr." letter to customers.
Answer: C
NEW QUESTION 39
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. The process information and analytical result of Company Y API
- B. Information deemed appropriate by the regulatory authority
- C. The process information and analytical result of Company X API
- D. The process information and the comparative analytical result of APIs from both companies
Answer: D
NEW QUESTION 40
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and early technical design
- B. Early technical design and product release
- C. Concept development and validation
- D. Product release and validation
Answer: A
NEW QUESTION 41
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
- A. Pre-clinical studies
- B. Phase I clinical trials
- C. Phase III clinical trials
- D. Phase I and II clinical trials
Answer: C
NEW QUESTION 42
What is the LAST stage in the development of a quality risk management process for a medical device?
- A. Risk reduction
- B. Risk analysis
- C. Risk acceptance
- D. Risk evaluation
Answer: C
NEW QUESTION 43
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 4
- B. Module 1
- C. Module 2
- D. Module 3
Answer: C
NEW QUESTION 44
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be labeled on the outside of the shipping package that it is intended for export.
- B. The product must not be in conflict with the laws of the country to which it is intended for export.
- C. The product must not be sold or offered for sale in domestic commerce.
- D. The product must not be in accord with the specifications of the foreign purchaser.
Answer: B
NEW QUESTION 45
A regulatory affairs professional has submitted a package for regulatory review.
According to the regulation, the regulatory authority will need to respond within 90 days of submission.
If there is no response after the deadline, what is the BEST approach?
- A. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any outstanding questions.
- B. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory authority's response time.
- C. Contact the local political representative and ask for intervention with the regulatory authority to obtain a decision regarding the submission.
- D. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made regarding the submission.
Answer: A
NEW QUESTION 46
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. Before the enactment of the regulation, through formal comments gathering process
- B. After the enactment of the regulation, through a product-specific meeting
- C. Before the enactment of the regulation, through the industry representative
- D. After the enactment of the regulation, through the industry representative
Answer: A
NEW QUESTION 47
Which of the following statements regarding the off-label use of drugs is CORRECT?
- A. The regulatory authority does not restrict physician prescribing for off-label indications or regulate the manufacturer's promotion for such use.
- B. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices as long as the marketing application is under review by the regulatory authority.
- C. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby increasing access to much needed drugs and devices.
- D. Although the regulatory authority reviews and approves drugs for specific indications, the approval does not limit the use of those drugs in clinical practice.
Answer: D
NEW QUESTION 48
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Develop a better brand-name drug in the same class.
- B. Develop a generic version of the drug.
- C. Explore litigation strategy for patent infringements on the drug.
- D. Conduct a Phase III study for a new unrelated indication of the drug.
Answer: B
NEW QUESTION 49
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Efficacy and material
- B. Compatibility and safety
- C. Safety and efficacy
- D. Volume and material
Answer: B
NEW QUESTION 50
The requirements for document control are located in which of the following documents?
- A. ICH guidelines
- B. ISO 13485
- C. IEC 60601
- D. WHO guidelines
Answer: B
NEW QUESTION 51
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Request documentation from the sub-contractor.
- B. Request an inspection from a regulatory authority.
- C. Ask the vendor to take responsibility.
- D. Document and perform audits.
Answer: D
NEW QUESTION 52
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Apply for review of the additional part of the product as a pharmaceutical product in Country
- B. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- C. Examine decisions made about similar products in Country Y to propose the classification of the product.
- D. Submit the product for review as a pharmaceutical product in Country Y.
Answer: A
NEW QUESTION 53
A request was received from a regulatory authority asking the company to conduct product testing in compliance with a newly issued regulation.
What should be done. What action should the company take FIRST?
- A. Consult with colleagues about the request.
- B. Send a letter back to the regulatory authority indicating why the regulation does not apply to the product.
- C. Initiate testing immediately to ensure compliance.
- D. Contact the regulatory authority that issued this request and discuss the requirement.
Answer: D
NEW QUESTION 54
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Detailed CV of all investigators
- B. Randomization scheme and codes
- C. Protocol and protocol amendments
- D. List of lECs or lRBs
Answer: A
NEW QUESTION 55
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Increase the frequency of monitoring visits.
- B. Terminate the PI and inform the regulatory authorities.
- C. Inform the institution that granted a medical license to the Pi.
- D. Send a letter of complaint to the Ethics Committee that approved the site.
Answer: B
NEW QUESTION 56
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- B. Wait for the regulatory authority's final publication on its findings.
- C. Contact the regulatory authority to discuss its findings.
- D. Contact the regulatory authority to argue that its conclusions are wrong.
Answer: C
NEW QUESTION 57
Which of the following BEST describes the purpose of the ICH?
- A. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- B. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- C. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
- D. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
Answer: A
NEW QUESTION 58
......
Use Valid Exam RAC-US by TestValid Books For Free Website: https://lead2pass.testvalid.com/RAC-US-valid-exam-test.html